Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PAHC 
Phibro Animal Health Corporation (PAHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/24/2025: PAHC (4-star) is a STRONG-BUY. BUY since 24 days. Simulated Profits (7.19%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $43
1 Year Target Price $43
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 98.05% | Avg. Invested days 49 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.75B USD | Price to earnings Ratio 25.8 | 1Y Target Price 43 |
Price to earnings Ratio 25.8 | 1Y Target Price 43 | ||
Volume (30-day avg) 4 | Beta 0.77 | 52 Weeks Range 16.03 - 46.42 | Updated Date 11/24/2025 |
52 Weeks Range 16.03 - 46.42 | Updated Date 11/24/2025 | ||
Dividends yield (FY) 1.15% | Basic EPS (TTM) 1.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate 0.6033 | Actual 0.73 |
Profitability
Profit Margin 4.84% | Operating Margin (TTM) 13.42% |
Management Effectiveness
Return on Assets (TTM) 8.55% | Return on Equity (TTM) 23.79% |
Valuation
Trailing PE 25.8 | Forward PE 10.57 | Enterprise Value 2387240100 | Price to Sales(TTM) 1.25 |
Enterprise Value 2387240100 | Price to Sales(TTM) 1.25 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA 13.2 | Shares Outstanding 20447574 | Shares Floating 20286665 |
Shares Outstanding 20447574 | Shares Floating 20286665 | ||
Percent Insiders 0.76 | Percent Institutions 99.3 |
Upturn AI SWOT
Phibro Animal Health Corporation
Company Overview
History and Background
Phibro Animal Health Corporation was founded in 1916 as Philipp Brothers, initially focusing on trading metals and minerals. It evolved into animal health and nutrition in the mid-20th century, becoming a publicly traded company specializing in animal health solutions.
Core Business Areas
- Animal Health: Develops, manufactures, and markets a broad range of animal health and mineral nutritional products for livestock, including poultry, swine, beef cattle, and dairy cattle. This includes medicated feed additives (MFAs), nutritional specialty products, vaccines, and other pharmaceuticals.
- Nutritional Specialties: Produces and markets nutritional specialty products, primarily for the animal feed industry, designed to improve animal nutrition and performance.
- Performance Alternatives: Provides solutions for production challenges, including alternatives to antibiotics. Focuses on improving animal welfare and productivity.
Leadership and Structure
The leadership team includes Jack Langan (President & CEO) and Dean Warras (CFO). The organizational structure consists of functional departments like R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Medicated Feed Additives (MFAs): Phibro's MFAs are used to prevent and control diseases in livestock, improving overall animal health and productivity. Market share varies by region and product, facing competition from Elanco and Zoetis. Revenue data is not specifically broken out.
- Nutritional Specialty Products: These products enhance animal nutrition, leading to better growth and feed efficiency. Competitors include DSM and ADM. Market share varies and specific revenue details are not provided, but these products contribute significantly to Phibro's revenue.
- OmniGenu00ae: A nutritional specialty product designed to support immune function in dairy cattle. Competitors are similar to nutritional specialty products. Performance details for this product alone are not publicly broken out.
Market Dynamics
Industry Overview
The animal health industry is driven by increasing global demand for meat, milk, and eggs, alongside growing concerns about animal welfare and food safety. It's characterized by innovation in pharmaceuticals, vaccines, and nutritional solutions.
Positioning
Phibro is a mid-sized player in the animal health industry, focusing on providing integrated solutions to livestock producers. Its competitive advantages include a broad product portfolio, global reach, and established relationships with customers.
Total Addressable Market (TAM)
The global animal health market is expected to reach several billion dollars. Phibro's TAM encompasses the livestock production sector, estimated at 40-50 billion, and is positioned to capture market share by offering comprehensive animal health solutions.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global distribution network
- Strong customer relationships
- Experience in regulatory affairs
- Focus on innovation
Weaknesses
- Reliance on a few key products
- Exposure to commodity price fluctuations
- Limited presence in companion animal health
- Competition from larger players
- Geographic concentration of sales
Opportunities
- Expanding into emerging markets
- Developing new products and technologies
- Acquiring complementary businesses
- Increasing focus on sustainability
- Growth in aquaculture
Threats
- Regulatory changes
- Increased competition
- Disease outbreaks
- Economic downturns
- Animal Activist Groups
Competitors and Market Share
Key Competitors
- ELAN
- ZOETIS
- MRK
Competitive Landscape
Phibro competes with larger animal health companies, focusing on specific market segments and regions. Its competitive advantages include a broad product portfolio and customer relationships, while disadvantages include smaller size and limited resources.
Major Acquisitions
Abic Biological Laboratories
- Year: 2021
- Acquisition Price (USD millions): 90
- Strategic Rationale: Expanded Phibrou2019s vaccine portfolio and strengthened its presence in aquaculture.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires analysis of revenue, income, and market share over the past several years.
Future Projections: Future projections are typically based on analyst estimates and company guidance.
Recent Initiatives: Recent initiatives include product launches, acquisitions, and expansions into new markets.
Summary
Phibro Animal Health Corporation is a mid-sized player in a competitive market with a long history. Its strengths lie in its diverse product offerings and global reach. The company needs to look out for increased regulation in the industry, as well as being able to compete with the larger animal health companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share percentages are estimates and may vary. Financial performance is subject to change based on company filings and market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phibro Animal Health Corporation
Exchange NASDAQ | Headquaters Teaneck, NJ, United States | ||
IPO Launch date 2014-04-11 | Chairman, President & CEO Mr. Jack Clifford Bendheim | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2475 | Website https://www.pahc.com |
Full time employees 2475 | Website https://www.pahc.com | ||
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.